LeRoy Coop
Departments
Cash Bids
Market Data
News
Ag Commentary
Weather
Resources
|
TKO Could be a Knock-OutSummary
The Chart of the Day belongs to the sports and entertainment company TKO Group (TKO) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 9/16 the stock gained 3.01%. TKO Group Holdings, Inc. operates as a sports and entertainment company. The company produces and licenses live events, television programs, and long-form and short-form content, reality series, and other filmed entertainment on digital and linear channels and via pay-per-view. It is involved in the merchandising of video games, apparel, equipment, trading cards, memorabilia, digital goods, and toys, as well as sale of travel packages and tickets. In addition, the company engages in the corporate sponsorships and advertising business, which offers sale of in-venue and in-broadcast advertising assets, content product integration, and digital impressions. The company was incorporated in 2023 and is based in New York, New York. TKO Group Holdings, Inc. is a subsidiary of Endeavor Group Holdings, Inc. Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.
Sponsored Message from MIRA Pharmaceuticals (MIRA)
MIRA Pharmaceuticals (MIRA), a pre-clinical stage company developing treatments for neurological and neuropsychiatric disorders, announced today that it is making significant progress on its oral ketamine analog, Ketamir-2. They're working on a capsule formulation for clinical trials and on track for an IND filing with the FDA by December 2024. MIRA aims to see initial signs of effectiveness in humans by 2025 through strategic clinical trial designs, focusing on neuropathic pain as the primary target. They're also exploring using Ketamir-2 for depression and PTSD.
The above is a paid advertisement. Barchart.com is not affiliated with nor does it endorse this content. It is for informational purposes only and not intended to be investing advice.
Barchart Technical Indicators:
Fundamental Factors:
Analysts and Investor Sentiment -- I don't buy stocks because everyone else is buying but I do realize that if major firms and investors are dumping a stock it's hard to make money swimming against the tide:
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis. On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. |
|